Nuvilex, Inc. in Advanced-Stage Discussions to Acquire Pancreatic Cancer Treatment Technology

SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB: NVLX) announces discussions are at an advanced stage with one of the world’s most experienced cell therapy companies to acquire their pancreatic cancer treatment technology.

The planned acquisition by Nuvilex would involve therapeutic treatment potential for pancreatic cancer, an aggressive, invasive disease responsible for 37,000 annual deaths in the U.S. alone. This acquisition will enable Nuvilex to provide encapsulated, living cells engineered to target tumors in patients with minimal collateral tissue damage. In completed clinical studies on pancreatic cancers, this treatment protocol has been shown to double life expectancy over present conventional pancreatic cancer therapy.

Pancreatic cancer is a particularly insidious form of the disease because it often does not show overt symptoms and therefore is not diagnosed until in an advanced stage. Even the best treatments for pancreatic cancer often extend life by only a few months. Less than 5% of patients diagnosed with this disease live longer than 5 years. The company’s technology for creating, maintaining, and providing the appropriate cells to combat this disease will be rapidly activated once this agreement is completed.

Dr. Robert F. Ryan, Nuvilex’s Chief Executive, stated, “We are encouraged by developments to date in these discussions and are extremely excited by the prospect of bringing this technology into Nuvilex. It has been a passion of ours to aid in the development of individualized therapies and this incredible opportunity will allow the Company to do just that. Expanding on the opportunity to provide personalized medicine for patients with appropriate needs will ultimately include other therapeutic interventions. By owning this advanced therapeutic technology, Nuvilex will become a significant player in the biotechnology arena, will dramatically open opportunities for our interaction with other companies, and will enable Nuvilex to stand out significantly from its direct competitors.”

We at Nuvilex are…

a Green Company believing in “Good for You, Good for the Environment” and are expanding our natural product lines and making important strides to enter into biotechnology (www.nuvilex.com). Current products include Cinnergen™ for healthy glucose maintenance; Cinnechol™ to maintain healthy lipids and cardiovasculature; Cinnsational™ to decrease detrimental alcohol effects; Talsyn™ for keloids, erythema, and scar management; NumaDerm™ cosmetic products; Citroxin™ and Oraphyte™ antimicrobial and antinematodal agents; Reme-Flu™, Legacy Biotechnologies’ flu combating regimen; and Virgin® and Infinitink®, heavy-metal-free tattoo inks.

Safe Harbor Statement

This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.



CONTACT:

Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
[email protected]

KEYWORDS:   United States  North America  Arizona

INDUSTRY KEYWORDS:   Health  Biotechnology  Fitness & Nutrition  Oncology  General Health

MEDIA:

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.